Compare Cytokinetics Inc (CYTK) vs Vanguard Total World Stock Index Fund ETF (VT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Vanguard Total World Stock Index Fund ETF — how do they compare? Cytokinetics Inc trades at $62.72 (market cap $8.62B), while Vanguard Total World Stock Index Fund ETF trades at $159.73 (market cap $101.70B). The key difference: Vanguard Total World Stock Index Fund ETF is far larger — about 11.8× Cytokinetics Inc's market cap, and Vanguard Total World Stock Index Fund ETF is trading nearer its 52-week high, Cytokinetics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Vanguard Total World Stock Index Fund ETF for 53 Days on average.
| CYTK | VT | |
|---|---|---|
Market Cap | $8.62B | $101.70B |
Volume | 2,594,626 | 1,783,794 |
Sector | Health | Broad Market / Factor |
52-Week High | $87.26 | $162.39 |
52-Week Low | $54.76 | $134.19 |
Typical Hold Time | 19 Days | 53 Days |
Enterprise Value | $8.72B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.48, up 2.23% today, but faces bearish technical signals with 18 sell indicators versus 4 buy signals. The company shows strong revenue growth potential with recent positive Phase 3 trial results for aficamten in non-obstructive HCM, though it operates at significant losses with a -1,321% net income margin. Cash flow remains heavily dependent on financing activities, with operating cash flow negative at -$555 million in 2026.
Wall Street maintains strong bullish sentiment with 97% buy ratings and a $112.60 consensus price target, representing 80% upside potential. Key risks include continued cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization of pipeline drugs. The stock's valuation appears stretched at 114x sales given current financial performance.
VT, the Vanguard Total World Stock ETF, trades at $159.39, down 0.16% on the day. Technical indicators show a bearish bias with moving averages signaling selling pressure, while oscillators remain neutral. The ETF offers broad global diversification with over 9,700 stocks and a low expense ratio of 0.06%, though key valuation ratios like P/E and P/B are not disclosed in the provided data. Recent news highlights its role as a core holding for long-term investors seeking worldwide exposure.
The outlook for VT is supported by its cost efficiency and diversification benefits, but near-term technical weakness and competitive pressures from lower-fee alternatives pose risks. Investor sentiment is mixed, with some analysts favoring VT for its comprehensive coverage, while others point to higher expenses relative to peers. Macroeconomic uncertainties and trade tensions could impact global equity returns, affecting VT's performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Vanguard Total World Stock Index Fund ETF
VT is a foundational, low-cost ETF that seeks to track the FTSE Global All Cap Index, providing exposure to nearly 10,000 stocks across developed and emerging markets worldwide, including the United States. It serves as a single-ticker solution for total global equity diversification, capturing approximately 98% of the world's investable market capitalization.
Read more on VT →
